Adagio Medical (ADGM) Expected to Announce Earnings on Monday

Adagio Medical (NASDAQ:ADGM) is expected to be releasing its results before the market opens on Monday, April 6th. Analysts expect Adagio Medical to post earnings of ($0.31) per share for the quarter.

Adagio Medical (NASDAQ:ADGM) last released its earnings results on Friday, March 27th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.10.

Adagio Medical Price Performance

Shares of NASDAQ:ADGM opened at $1.22 on Monday. The company has a quick ratio of 0.68, a current ratio of 0.84 and a debt-to-equity ratio of 1.96. The stock has a market cap of $25.84 million, a PE ratio of -0.71 and a beta of 0.12. The company’s fifty day moving average is $1.02 and its 200 day moving average is $1.17. Adagio Medical has a 52 week low of $0.63 and a 52 week high of $2.87.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Cresset Asset Management LLC bought a new stake in shares of Adagio Medical during the 2nd quarter valued at about $39,000. Geode Capital Management LLC lifted its holdings in Adagio Medical by 88.6% in the fourth quarter. Geode Capital Management LLC now owns 68,342 shares of the company’s stock worth $71,000 after buying an additional 32,100 shares during the period. Hudson Bay Capital Management LP purchased a new stake in Adagio Medical in the fourth quarter worth about $308,000. Armistice Capital LLC bought a new stake in Adagio Medical during the 4th quarter valued at approximately $497,000. Finally, Adage Capital Partners GP L.L.C. grew its holdings in shares of Adagio Medical by 17.3% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 821,261 shares of the company’s stock worth $1,068,000 after acquiring an additional 121,261 shares during the period. 48.08% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have recently issued reports on ADGM. Lake Street Capital started coverage on Adagio Medical in a research note on Tuesday, December 2nd. They set a “buy” rating and a $4.00 price objective on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Adagio Medical in a report on Monday, December 22nd. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Adagio Medical currently has a consensus rating of “Hold” and an average price target of $4.00.

About Adagio Medical

Adagio Medical, Inc (NASDAQ: ADGM) is a medical device company focused on the development and commercialization of a noninvasive system for monitoring intracranial pressure (ICP). The company’s proprietary technology uses tympanic membrane displacement to provide clinicians with real-time estimates of ICP without the risks associated with invasive catheter methods. This approach is designed to improve patient safety, reduce complications, and streamline neurological monitoring in acute and critical care settings.

At the core of Adagio Medical’s pipeline is its ADGM System, which is intended for use in hospitals, emergency departments, and other clinical environments where rapid and accurate assessment of ICP is crucial.